MedTrace Logo

A Study of ABT-414 in Subjects With Solid Tumors

NCT01741727 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 57

Last updated 2017-11-20

No results posted yet for this study

Summary

A study of ABT-414 in subjects with solid tumors.

Conditions

  • Squamous Cell Tumors

Interventions

DRUG

ABT-414

ABT-414 will be administered by intravenous infusion.

Sponsors & Collaborators

  • AbbVie (prior sponsor, Abbott)

    lead INDUSTRY

Principal Investigators

  • Christopher Ocampo, MD · AbbVie

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
99 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2012-10-31
Primary Completion
2015-11-30
Completion
2015-11-30

Countries

  • United States
  • Canada

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01741727 on ClinicalTrials.gov